GCP
OVID icon

GSA Capital Partners’s Ovid Therapeutics OVID Stock Holding History

GSA Capital Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-123,969
Closed -$275K – 2054
2026
Q1 		$275K Buy
123,969
+15,635
+14% +$28K 0.02% 1298
2025
Q4 		$177K Sell
108,334
-157,659
-59% -$243K 0.02% 1441
2025
Q3 		$346K Sell
265,993
-476,197
-64% -$413K 0.03% 1114
2025
Q2 		$245K Buy
742,190
+302,087
+69% +$91K 0.02% 1392
2025
Q1 		$137K Buy
440,103
+316,520
+256% +$195K 0.01% 1467
2024
Q4 		$115K Sell
123,583
-136,926
-53% -$153K 0.01% 1502
2024
Q3 		$307K Buy
260,509
+141,002
+118% +$147K 0.02% 1200
2024
Q2 		$92K Buy
+119,507
New +$333K 0.01% 1534
2021
Q2 		– Sell
-75,888
Closed -$305K – 1526
2021
Q1 		$305K Sell
75,888
-115,945
-60% -$385K 0.05% 638
2020
Q4 		$443K Buy
191,833
+134,959
+237% +$629K 0.07% 494
2020
Q3 		$326K Buy
+56,874
New +$381K 0.05% 677

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

GSA Capital Partners's OVID Position: Q2 2026 in Review

GSA Capital Partners sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 123,969 shares — an estimated $275K sold.

GSA Capital Partners first reported a position in OVID in Q3 2020 and held it in 11 quarters. The position peaked at $443K in Q4 2020. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • GSA Capital Partners reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 123,969 Ovid Therapeutics shares in Q2 2026, an estimated $275K.
  • GSA Capital Partners first reported a position in Ovid Therapeutics in Q3 2020 and held it in 11 quarters.
  • GSA Capital Partners's Ovid Therapeutics position peaked at $443K in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.